A clinical-stage biotech developing targeted alpha radiopharmaceuticals for solid tumors, Aktis Oncology builds its medicines from tiny engineered proteins called miniproteins that slip deep into tumors and clear quickly from the body. Its lead candidate targets Nectin-4, found on bladder and other cancers, while a second program targets B7-H3 for prostate and lung cancers. The company has a discovery collaboration with Eli Lilly and is building its own manufacturing facility.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +6.35M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.